NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

生物醫藥品受託製造的全球市場:來源,各產品,各類服務的市場規模,佔有率及趨勢分析,各市場區隔預測(2021年∼2028年)

Biopharmaceuticals Contract Manufacturing Market Size, Share & Trends Analysis Report By Source (Mammalian, Non-mammalian), By Product (Biologics, Biosimilars), By Service (Process Development), And Segment Forecasts, 2021 - 2028

出版商 Grand View Research, Inc. 商品編碼 988057
出版日期 內容資訊 英文 139 Pages
商品交期: 2-10個工作天內
價格
生物醫藥品受託製造的全球市場:來源,各產品,各類服務的市場規模,佔有率及趨勢分析,各市場區隔預測(2021年∼2028年) Biopharmaceuticals Contract Manufacturing Market Size, Share & Trends Analysis Report By Source (Mammalian, Non-mammalian), By Product (Biologics, Biosimilars), By Service (Process Development), And Segment Forecasts, 2021 - 2028
出版日期: 2021年01月20日內容資訊: 英文 139 Pages
簡介

全球生物醫藥品受託製造的市場規模在預測期間內預計將以5.7%的年複合成長率擴大,2028年之前達到251億美元。生物製藥管道的增長和缺乏足夠的製造能力是推動主要聚合物製造商和首席營銷官(CMO)之間建立夥伴關係的兩個關鍵因素。合同製造商正在努力擴展其服務組合,以滿足法規標準和公司對新服務的需求。

本報告提供全球生物醫藥品受託製造市場相關調查分析,提供市場及產業預測,各市場區隔·各地區的預測,加上競爭情形相關的系統性資訊。

目錄

第1章 摘要整理

第2章 調查方法

第3章 市場變數,趨勢,範圍

  • 市場細分化和範圍
  • 市場機會分析
  • 趨勢分析
  • 開發平台分析
  • 製程發展的價格分析
  • 委託製造服務的滲透與成長預測的製圖,2020年
  • 生物醫藥品受託製造市場SWOT分析,要因別(政治及法律,經濟及技術性)
  • 產業分析-波特的五力分析
  • 受託製造的顧客關係管理

第4章 生物醫藥品受託製造市場:各來源市場估計·趨勢分析

  • 全球生物醫藥品受託製造市場:各來源市場趨勢分析
  • 哺乳類來源
  • 非哺乳類來源

第5章 生物醫藥品受託製造市場:各類服務市場估計·趨勢分析

  • 全球生物醫藥品受託製造市場:各類服務市場趨勢分析
  • 製程發展
    • 下游處理
    • 上游產業處理
  • 填充及最後加工工作
  • 分析及QC研究
  • 包裝

第6章 生物醫藥品受託製造市場:各產品市場估計·趨勢分析

  • 全球生物醫藥品受託製造市場:各產品市場趨勢分析
  • 生技藥品
    • 單株抗體
    • 重組蛋白質
    • 疫苗
  • 反義,RNAi,及分子療法
    • 其他
  • 生物相似藥
    • 全球生物相似藥市場,2016年∼2028年(百萬美元)

第7章 生物醫藥品受託製造市場:服務,醬汁(來源),及各產品的各地區市場的估計·趨勢分析

  • 各地區市場佔有率,2020年及2028年
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東·非洲(MEA)

第8章 競爭情形

  • 策略性架構
  • 市場進入分類
  • 企業簡介
    • Boehringer Ingelheim GmbH
    • Lonza
    • Inno Biologics Sdn Bhd
    • Rentschler Biotechnologie GmbH
    • JRS PHARMA
    • AGC Biologics
    • ProBioGen
    • FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
    • Toyobo
    • Samsung BioLogics
    • Thermo Fisher Scientific, Inc.
    • Binex Co., Ltd.
    • WuXi Biologics
    • AbbVie, Inc.
目錄
Product Code: GVR-2-68038-698-1

Biopharmaceuticals Contract Manufacturing Market Growth & Trends

The global biopharmaceuticals contract manufacturing market size is expected to reach USD 25.1 billion by 2028 registering a CAGR of 5.7%, according to a new report by Grand View Research, Inc. Growing biopharmaceutical pipeline and lack of adequate manufacturing capabilities are two key factors that are driving partnership between large molecule manufacturers and Contract Manufacturing Organizations (CMOs). Contract manufacturers are engaged in broadening their service portfolio to meet the company demands with respect to regulatory standards and new services.

The reliance of companies on CMOs for the production of biologics and biosimilars is expected to rise over the forecast period as a consequence of changes adopted by the CMOs. This is evident through growing investment in collaborations of companies with CMOs as well as continuous efforts taken up for expanding the service portfolio.

The supply chain of biopharmaceuticals remained robust and was largely unaffected worldwide during the coronavirus outburst. Also, biopharmaceutical contract manufacturers are observing increased demand related to the Covid-19 vaccine and therapeutics. Thus, the future holds numerous opportunities for the global market. For instance, in 2020, AstraZeneca and Oxford Biomedica signed a one-year clinical and commercial supply agreement for the manufacturing of AstraZeneca's Covid-19 vaccine candidate, AZD1222.

The future growth of CMOs is highly dependent on the promising opportunities offered by the biopharmaceutical industry, the bioprocessing industry, and the contract service industry. Expansion of fill-and-finish services and increasing robustness of venture capital investments for the life science sector are two important opportunities that are anticipated to drive the market. For instance, in 2019, Shanghai HaiHe Biopharma Co. Ltd. raised USD 146.6 million as venture capital for its large cancer drug portfolio, which they shall utilize along with their outsourcing partner Zhejiang Jiuzhou Pharmaceutical Co., Ltd.

Biopharmaceuticals Contract Manufacturing Market Report Highlights

Mammalian-based biopharmaceutical contract manufacturing captured the largest market share of over 59% in 2020 owing to the high penetration of mammalian expression system for biologics development

Out of all the services offered in this market, process development contributed to the largest share in 2020 owing to high capital investment, especially in the downstream process

The complexities associated with regulatory approval and good manufacturing practice pronounces the demand for the established contract manufacturers to ensure compliance with regulatory standards

The biologics contract manufacturing segment dominated the global market in 2020 owing to higher demand for biologics production

However, the biosimilar segment is estimated to register the fastest CAGR from 2021 to 2028 due to cost-saving advantages associated with biosimilars development

North America was the dominant regional market in 2020 due to the presence of an effective regulatory framework for biologics development in the U.S.

However, Asia Pacific is expected to emerge as the fastest-growing regional market from 2021 to 2028 owing to emerging countries, such as India and China, incorporating developments to sustain the competition

Several international companies are seeking outsourcing of biopharmaceutical production to Asian countries owing to the continuous expansion of Asian CMOs that offer services at a less price, as compared to the service providers based in western countries

Table of contents

Chapter 1 Executive Summary

  • 1.1 Market Snapshot

Chapter 2 Research Methodology

  • 2.1 Information Procurement
    • 2.1.1 Purchased Database
    • 2.1.2 GVR's Internal Database
  • 2.2 Data Analysis
  • 2.3 Market Formulation & Validation
  • 2.4 Approaches for Market Estimation
    • 2.4.1 Approach 1: Commodity Flow & Bottom Up Approach
    • 2.4.2 Approach 2: Top Down and Parent Market Analysis

Chapter 3 Market Variables, Trends& Scope

  • 3.1 Market Segmentation &Scope
    • 3.1.1 Market driver analysis
      • 3.1.1.1 Rise in investment by CMOs for capacity expansion
      • 3.1.1.2 Commercial success of biopharmaceuticals and consequent increase in demand for biopharmaceuticals
      • 3.1.1.2.1 Notable growth of biologics
      • 3.1.1.3 Robust biopharmaceuticals pipeline
      • 3.1.1.4 Cost and time saving benefits offered by contract services
    • 3.1.2 Market restraint analysis
      • 3.1.2.1 Limited outsourcing amongst well-established biopharmaceutical manufacturer
  • 3.2 Opportunity analysis
    • 3.2.1 Expansion of fill-and-finish CMOs
    • 3.2.2 Emergence of single-use bioprocessing equipment & solutions
    • 3.2.3 Funding & investments
  • 3.3 Trend Analysis
    • 3.3.1 Merger & acquisitions in CMO industry
    • 3.3.2 Trading of CMOs at strong EV/EBITDA multiples
    • 3.3.3 Current trends in biopharmaceutical industry
  • 3.4 Pipeline Analysis
    • 3.4.1 Distribution of products & projects in development stage by clinical phase
      • 3.4.1.1 Key finding of the analysis:
    • 3.4.2 Pipeline analysis for biosimilar drugs, as of February 2018
    • 3.4.3 Total global biopharmaceutical R&D spending
    • 3.4.4 Number of drugs in clinical development phase, 2015
  • 3.5 Pricing Analysis for Process Development
    • 3.5.1 Cell line/expression system pricing
    • 3.5.2 Bioreactor cost
    • 3.5.3 Operating and construction cost advantage due to single-use bioprocessing equipment
    • 3.5.4 Bioprocessing operating cost items and ranges
    • 3.5.5 Bioprocessing pricing analysis based on product type
    • 3.5.6 Downstream bioprocessing pricing analysis
      • 3.5.6.1 Cost analyses for buffer purchasing
  • 3.6 Penetration &Growth Prospect Mapping for Contract Manufacturing Service, 2020
  • 3.7 Biopharmaceuticals Contract Manufacturing Market - Swot Analysis, By Factor (Political & Legal, Economic And Technological)
  • 3.8 Industry Analysis - Porter's
  • 3.9 Customer Relationship Management in Contract Manufacturing
    • 3.9.1 Selection process of CMO
    • 3.9.2 Operations and quality oversight of CMOs

Chapter 4 Biopharmaceuticals Contract Manufacturing Market: Source Estimates & Trend Analysis

  • 4.1 Global Biopharmaceuticals Contract Manufacturing Market: Source Movement Analysis
  • 4.2 Mammalian Source
    • 4.2.1 Global mammalian source market, 2016 - 2028 (USD Million)
  • 4.3 Non-mammalian Source
    • 4.3.1 Global non-mammalian source market, 2016 - 2028 (USD Million)

Chapter 5 Biopharmaceuticals Contract Manufacturing Market: Service Estimates & Trend Analysis

  • 5.1 Global Biopharmaceuticals Contract Manufacturing Market: Service Movement Analysis
  • 5.2 Process Development
    • 5.2.1 Global process development market, 2016 - 2028 (USD Million)
    • 5.2.2 Downstream Processing
      • 5.2.2.1 Global downstream processing market, 2016 - 2028 (USD Million)
    • 5.2.3 Upstream Processing
      • 5.2.3.1 Global upstream processing market, 2016 - 2028 (USD Million)
  • 5.3 Fill & Finish Operations
    • 5.3.1 Global fill & finish operations market, 2016 - 2028 (USD Million)
  • 5.4 Analytical & QC Studies
    • 5.4.1 Global analytical & QC studies market, 2016 - 2028 (USD Million)
  • 5.5 Packaging
    • 5.5.1 Global contract packaging market, 2016 - 2028 (USD Million)

Chapter 6 Biopharmaceuticals Contract Manufacturing Market: Product Estimates & Trend Analysis

  • 6.1 Global Biopharmaceuticals Contract Manufacturing Market: Product Movement Analysis
  • 6.2 Biologics
    • 6.2.1 Global biologics market, 2016 - 2028 (USD Million)
    • 6.2.2 Monoclonal Antibodies
      • 6.2.2.1 Global monoclonal antibodies market, 2016 - 2028 (USD Million)
    • 6.2.3 Recombinant Proteins
      • 6.2.3.1 Global recombinant proteins market, 2016 - 2028 (USD Million)
    • 6.2.4 Vaccines
      • 6.2.4.1 Global vaccines market, 2016 - 2028 (USD Million)
  • 6.3 Antisense, RNAi, & Molecular Therapy
      • 6.3.1.1 Global antisense, RNAi, & molecular therapy market, 2016 - 2028 (USD Million)
    • 6.3.2 Others
      • 6.3.2.1 Global other product market, 2016 - 2028 (USD Million)
  • 6.4 Biosimilars
    • 6.4.1 Global biosimilars market, 2016 - 2028 (USD Million)

Chapter 7 Biopharmaceuticals Contract Manufacturing Market: Regional Estimates & Trend Analysis, by Service, Source, & Product

  • 7.1 Market Share by Region, 2020 & 2028
  • 7.2 North America
    • 7.2.1 Market, 2016 - 2028 (USD Million)
    • 7.2.2 The U.S.
      • 7.2.2.1 Market, by source, 2016 - 2028 (USD Million)
      • 7.2.2.2 Market, by service, 2016 - 2028 (USD Million)
      • 7.2.2.3 Market, by product, 2016 - 2028 (USD Million)
    • 7.2.3 Canada
      • 7.2.3.1 Market, by source, 2016 - 2028 (USD Million)
      • 7.2.3.2 Market, by service, 2016 - 2028 (USD Million)
      • 7.2.3.3 Market, by product, 2016 - 2028 (USD Million)
  • 7.3 Europe
    • 7.3.1 Market, 2016 - 2028 (USD Million)
    • 7.3.2 Germany
      • 7.3.2.1 Market, by source, 2016 - 2028 (USD Million)
      • 7.3.2.2 Market, by service, 2016 - 2028 (USD Million)
      • 7.3.2.3 Market, by product, 2016 - 2028 (USD Million)
    • 7.3.3 France
      • 7.3.3.1 Market, by source, 2016 - 2028 (USD Million)
      • 7.3.3.2 Market, by service, 2016 - 2028 (USD Million)
      • 7.3.3.3 Market, by product, 2016 - 2028 (USD Million)
  • 7.4 Asia Pacific
    • 7.4.1 Market, 2016 - 2028 (USD Million)
    • 7.4.2 China
      • 7.4.2.1 Market, by source, 2016 - 2028 (USD Million)
      • 7.4.2.2 Market, by service, 2016 - 2028 (USD Million)
      • 7.4.2.3 Market, by product, 2016 - 2028 (USD Million)
    • 7.4.3 India
      • 7.4.3.1 Market, by source, 2016 - 2028 (USD Million)
      • 7.4.3.2 Market, by service, 2016 - 2028 (USD Million)
      • 7.4.3.3 Market, by product, 2016 - 2028 (USD Million)
  • 7.5 Latin America
    • 7.5.1 Market, 2016 - 2028 (USD Million)
    • 7.5.2 Brazil
      • 7.5.2.1 Market, by source, 2016 - 2028 (USD Million)
      • 7.5.2.2 Market, by service, 2016 - 2028 (USD Million)
      • 7.5.2.3 Market, by product, 2016 - 2028 (USD Million)
  • 7.6 Middle East & Africa (MEA)
    • 7.6.1 Market, 2016 - 2028 (USD Million)
    • 7.6.2 South Africa
      • 7.6.2.1 Market, by source, 2016 - 2028 (USD Million)
      • 7.6.2.2 Market, by service, 2016 - 2028 (USD Million)
      • 7.6.2.3 Market, by product, 2016 - 2028 (USD Million)

Chapter 8 Competitive Landscape

  • 8.1 Strategy Framework
  • 8.2 Market Participation Categorization
  • 8.3 Company Profiles
    • 8.3.1 Boehringer Ingelheim GmbH
      • 8.3.1.1 Company overview
      • 8.3.1.2 Financial performance
      • 8.3.1.3 Product benchmarking
      • 8.3.1.4 Strategic initiatives
    • 8.3.2 Lonza
      • 8.3.2.1 Company overview
      • 8.3.2.2 Financial performance
      • 8.3.2.3 Product benchmarking
      • 8.3.2.4 Strategic initiatives
    • 8.3.3 Inno Biologics Sdn Bhd
      • 8.3.3.1 Company overview
      • 8.3.3.2 Financial performance
      • 8.3.3.3 Product benchmarking
      • 8.3.3.4 Strategic initiatives
    • 8.3.4 Rentschler Biotechnologie GmbH
      • 8.3.4.1 Company overview
      • 8.3.4.2 Financial performance
      • 8.3.4.3 Product benchmarking
      • 8.3.4.4 Strategic initiatives
    • 8.3.5 JRS PHARMA
      • 8.3.5.1 Company overview
      • 8.3.5.1.1 CELONIC AG
      • 8.3.5.2 Financial performance
      • 8.3.5.2.1 Financial performance
      • 8.3.5.3 Product benchmarking
      • 8.3.5.4 Strategic initiatives
    • 8.3.6 AGC Biologics
      • 8.3.6.1 Company overview
      • 8.3.6.2 BIOMEVA GmbH
      • 8.3.6.2.1 Company overview
      • 8.3.6.3 CMC Biologics
      • 8.3.6.3.1 Company overview
      • 8.3.6.4 Financial performance of AGC
      • 8.3.6.4.1 Financial performance of BIOMEVA GmbH
      • 8.3.6.4.2 Financial performance of CMC Biologics
      • 8.3.6.5 Product benchmarking
      • 8.3.6.6 Strategic initiatives
      • 8.3.6.6.1 Biomeva GmbH
      • 8.3.6.6.2 CMC Biologics
    • 8.3.7 ProBioGen
      • 8.3.7.1 Company overview
      • 8.3.7.2 Financial performance
      • 8.3.7.3 Product benchmarking
      • 8.3.7.4 Strategic initiatives
    • 8.3.8 FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
      • 8.3.8.1 Company overview
      • 8.3.8.2 Financial performance
      • 8.3.8.3 Product benchmarking
      • 8.3.8.4 Strategic initiatives
    • 8.3.9 TOYOBO CO., LTD.
      • 8.3.9.1 Company overview
      • 8.3.9.2 Financial performance
      • 8.3.9.3 Product benchmarking
      • 8.3.9.4 Strategic initiatives
    • 8.3.10 Samsung BioLogics
      • 8.3.10.1 Company overview
      • 8.3.10.2 Financial performance
      • 8.3.10.3 Product benchmarking
      • 8.3.10.4 Strategic initiatives
    • 8.3.11 Thermo Fisher Scientific, Inc.
      • 8.3.11.1 Company Overview
      • 8.3.11.2 Patheon
      • 8.3.11.2.1 Company overview
      • 8.3.12.1.1.1 DPx
      • 8.3.12.2 Financial Performance of Thermo Fisher Scientific, Inc.
      • 8.3.12.2.1 Financial performance of Patheon
      • 8.3.12.4 Product benchmarking
      • 8.3.12.5 Strategic initiatives
    • 8.3.12 Binex Co., Ltd.
      • 8.3.12.1 Company overview
      • 8.3.12.2 Financial performance
      • 8.3.12.3 Product benchmarking
    • 8.3.13 WuXi Biologics
      • 8.3.13.1 Company overview
      • 8.3.13.2 Financial performance
      • 8.3.13.3 Product benchmarking
      • 8.3.13.4 Strategic initiatives
    • 8.3.14 AbbVie, Inc.
      • 8.3.14.1 Company overview
      • 8.3.14.2 Financial performance
      • 8.3.14.3 Product benchmarking
      • 8.3.14.4 Strategic initiatives

List of Tables

  • TABLE 1 2015 pipeline of biologics
  • TABLE 2 Distribution of products and projects by phase
  • TABLE 3 Distribution of products and projects by therapeutic area and phase
  • TABLE 4 Pipeline analysis for biosimilar drugs, as of February 2018
  • TABLE 5 Market for total global bio/pharmaceutical R&D spending
  • TABLE 6 Drugs in clinical development phase, 2015
  • TABLE 7 Bioreactor cost
  • TABLE 8 Bioprocessing operating cost items and ranges
  • TABLE 9 Summary of lowest facility manufacturing costs, by facility type (assuming a minimum mAb manufacture of 100 kg per year)
  • TABLE 10 Average annual costs for in - house buffer preparation (by liter of production)
  • TABLE 11 Some commercially available biopharmaceuticals and biologics produced using mammalian cell lines
  • TABLE 12 Some commercially available biopharmaceuticals and biologics produced using mammalian cell lines
  • TABLE 13 Some biopharmaceuticals produced using S. cerevisiae
  • TABLE 14 Some commercially available biopharmaceuticals and biologics produced using microbial cell lines
  • TABLE 15 Global sales of top biologics in 2014
  • TABLE 16 Some commercially available MAb products
  • TABLE 17 Number of MAb products by indication area, 2015
  • TABLE 18 Time and budget requirement for different stages of vaccine development
  • TABLE 19 North America biopharmaceuticals contract manufacturing market estimates, by source, 2016 - 2020 (USD Million)
  • TABLE 20 North America biopharmaceuticals contract manufacturing market forecasts, by source, 2021 - 2028 (USD Million)
  • TABLE 21 North America biopharmaceuticals contract manufacturing market estimates, by service, 2016 - 2020 (USD Million)
  • TABLE 22 North America biopharmaceuticals contract manufacturing market forecasts, by service, 2021 - 2028 (USD Million)
  • TABLE 23 North America biopharmaceuticals process development market estimates, by service, 2016 - 2020 (USD Million)
  • TABLE 24 North America biopharmaceuticals process development market forecasts, by service, 2021 - 2028 (USD Million)
  • TABLE 25 North America biopharmaceuticals contract manufacturing market estimates, by product, 2016 - 2020 (USD Million)
  • TABLE 26 North America biopharmaceuticals contract manufacturing market forecasts, by product, 2021 - 2028 (USD Million)
  • TABLE 27 North America biologics contract manufacturing market estimates, by product, 2016 - 2020 (USD Million)
  • TABLE 28 North America biologics contract manufacturing market forecasts, by product, 2021 - 2028 (USD Million)
  • TABLE 29 The U.S. biopharmaceuticals contract manufacturing market estimates, by source, 2016 - 2020 (USD Million)
  • TABLE 30 The U.S. biopharmaceuticals contract manufacturing market forecasts, by source, 2021 - 2028 (USD Million)
  • TABLE 31 The U.S. biopharmaceuticals contract manufacturing market estimates, by service, 2016 - 2020 (USD Million)
  • TABLE 32 The U.S. biopharmaceuticals contract manufacturing market forecasts, by service, 2021 - 2028 (USD Million)
  • TABLE 33 The U.S. biopharmaceuticals process development market estimates, by service, 2016 - 2020 (USD Million)
  • TABLE 34 The U.S. biopharmaceuticals process development market forecasts, by service, 2021 - 2028 (USD Million)
  • TABLE 35 The U.S. biopharmaceuticals contract manufacturing market estimates, by product, 2016 - 2020 (USD Million)
  • TABLE 36 The U.S. biopharmaceuticals contract manufacturing market forecasts, by product, 2021 - 2028 (USD Million)
  • TABLE 37 The U.S. biologics contract manufacturing market estimates, by product, 2016 - 2020 (USD Million)
  • TABLE 38 The U.S. biologics contract manufacturing market forecasts, by product, 2021 - 2028 (USD Million)
  • TABLE 39 Canada biopharmaceuticals contract manufacturing market estimates, by source, 2016 - 2020 (USD Million)
  • TABLE 40 Canada biopharmaceuticals contract manufacturing market forecasts, by source, 2021 - 2028 (USD Million)
  • TABLE 41 Canada biopharmaceuticals contract manufacturing market estimates, by service, 2016 - 2020 (USD Million)
  • TABLE 42 Canada biopharmaceuticals contract manufacturing market forecasts, by service, 2021 - 2028 (USD Million)
  • TABLE 43 Canada biopharmaceuticals process development market estimates, by service, 2016 - 2020 (USD Million)
  • TABLE 44 Canada biopharmaceuticals process development market forecasts, by service, 2021 - 2028 (USD Million)
  • TABLE 45 Canada biopharmaceuticals contract manufacturing market estimates, by product, 2016 - 2020 (USD Million)
  • TABLE 46 Canada biopharmaceuticals contract manufacturing market forecasts, by product, 2021 - 2028 (USD Million)
  • TABLE 47 Canada biologics contract manufacturing market estimates, by product, 2016 - 2020 (USD Million)
  • TABLE 48 Canada biologics contract manufacturing market forecasts, by product, 2021 - 2028 (USD Million)
  • TABLE 49 Europe biopharmaceuticals contract manufacturing market estimates, by source, 2016 - 2020 (USD Million)
  • TABLE 50 Europe biopharmaceuticals contract manufacturing market forecasts, by source, 2021 - 2028 (USD Million)
  • TABLE 51 Europe biopharmaceuticals contract manufacturing market estimates, by service, 2016 - 2020 (USD Million)
  • TABLE 52 Europe biopharmaceuticals contract manufacturing market forecasts, by service, 2021 - 2028 (USD Million)
  • TABLE 53 Europe biopharmaceuticals process development market estimates, by service, 2016 - 2020 (USD Million)
  • TABLE 54 Europe biopharmaceuticals process development market forecasts, by service, 2021 - 2028 (USD Million)
  • TABLE 55 Europe biopharmaceuticals contract manufacturing market estimates, by product, 2016 - 2020 (USD Million)
  • TABLE 56 Europe biopharmaceuticals contract manufacturing market forecasts, by product, 2021 - 2028 (USD Million)
  • TABLE 57 Europe biologics contract manufacturing market estimates, by product, 2016 - 2020 (USD Million)
  • TABLE 58 Europe biologics contract manufacturing market forecasts, by product, 2021 - 2028 (USD Million)
  • TABLE 59 Germany biopharmaceuticals contract manufacturing market estimates, by source, 2016 - 2020 (USD Million)
  • TABLE 60 Germany biopharmaceuticals contract manufacturing market forecasts, by source, 2021 - 2028 (USD Million)
  • TABLE 61 Germany biopharmaceuticals contract manufacturing market estimates, by service, 2016 - 2020 (USD Million)
  • TABLE 62 Germany biopharmaceuticals contract manufacturing market forecasts, by service, 2021 - 2028 (USD Million)
  • TABLE 63 Germany biopharmaceuticals process development market estimates, by service, 2016 - 2020 (USD Million)
  • TABLE 64 Germany biopharmaceuticals process development market forecasts, by service, 2021 - 2028 (USD Million)
  • TABLE 65 Germany biopharmaceuticals contract manufacturing market estimates, by product, 2016 - 2020 (USD Million)
  • TABLE 66 Germany biopharmaceuticals contract manufacturing market forecasts, by product, 2021 - 2028 (USD Million)
  • TABLE 67 Germany biologics contract manufacturing market estimates, by product, 2016 - 2020 (USD Million)
  • TABLE 68 Germany biologics contract manufacturing market forecasts, by product, 2021 - 2028 (USD Million)
  • TABLE 69 France biopharmaceuticals contract manufacturing market estimates, by source, 2016 - 2020 (USD Million)
  • TABLE 70 France biopharmaceuticals contract manufacturing market forecasts, by source, 2021 - 2028 (USD Million)
  • TABLE 71 France biopharmaceuticals contract manufacturing market estimates, by service, 2016 - 2020 (USD Million)
  • TABLE 72 France biopharmaceuticals contract manufacturing market forecasts, by service, 2021 - 2028 (USD Million)
  • TABLE 73 France biopharmaceuticals process development market estimates, by service, 2016 - 2020 (USD Million)
  • TABLE 74 France biopharmaceuticals process development market forecasts, by service, 2021 - 2028 (USD Million)
  • TABLE 75 France biopharmaceuticals contract manufacturing market estimates, by product, 2016 - 2020 (USD Million)
  • TABLE 76 France biopharmaceuticals contract manufacturing market forecasts, by product, 2021 - 2028 (USD Million)
  • TABLE 77 France biologics contract manufacturing market estimates, by product, 2016 - 2020 (USD Million)
  • TABLE 78 France biologics contract manufacturing market forecasts, by product, 2021 - 2028 (USD Million)
  • TABLE 79 Asia pacific biopharmaceuticals contract manufacturing market estimates, by source, 2016 - 2020 (USD Million)
  • TABLE 80 Asia pacific biopharmaceuticals contract manufacturing market forecasts, by source, 2021 - 2028 (USD Million)
  • TABLE 81 Asia pacific biopharmaceuticals contract manufacturing market estimates, by service, 2016 - 2020 (USD Million)
  • TABLE 82 Asia pacific biopharmaceuticals contract manufacturing market forecasts, by service, 2021 - 2028 (USD Million)
  • TABLE 83 Asia pacific biopharmaceuticals process development market estimates, by service, 2016 - 2020 (USD Million)
  • TABLE 84 Asia pacific biopharmaceuticals process development market forecasts, by service, 2021 - 2028 (USD Million)
  • TABLE 85 Asia pacific biopharmaceuticals contract manufacturing market estimates, by product, 2016 - 2020 (USD Million)
  • TABLE 86 Asia pacific biopharmaceuticals contract manufacturing market forecasts, by product, 2021 - 2028 (USD Million)
  • TABLE 87 Asia pacific biologics contract manufacturing market estimates, by product, 2016 - 2020 (USD Million)
  • TABLE 88 Asia pacific biologics contract manufacturing market forecasts, by product, 2021 - 2028 (USD Million)
  • TABLE 89 China biopharmaceuticals contract manufacturing market estimates, by source, 2016 - 2020 (USD Million)
  • TABLE 90 China biopharmaceuticals contract manufacturing market forecasts, by source, 2021 - 2028 (USD Million)
  • TABLE 91 China biopharmaceuticals contract manufacturing market estimates, by service, 2016 - 2020 (USD Million)
  • TABLE 92 China biopharmaceuticals contract manufacturing market forecasts, by service, 2021 - 2028 (USD Million)
  • TABLE 93 China biopharmaceuticals process development market estimates, by service, 2016 - 2020 (USD Million)
  • TABLE 94 China biopharmaceuticals process development market forecasts, by service, 2021 - 2028 (USD Million)
  • TABLE 95 China biopharmaceuticals contract manufacturing market estimates, by product, 2016 - 2020 (USD Million)
  • TABLE 96 China biopharmaceuticals contract manufacturing market forecasts, by product, 2021 - 2028 (USD Million)
  • TABLE 97 China biologics contract manufacturing market estimates, by product, 2016 - 2020 (USD Million)
  • TABLE 98 China biologics contract manufacturing market forecasts, by product, 2021 - 2028 (USD Million)
  • TABLE 99 India biopharmaceuticals contract manufacturing market estimates, by source, 2016 - 2020 (USD Million)
  • TABLE 100 India biopharmaceuticals contract manufacturing market forecasts, by source, 2021 - 2028 (USD Million)
  • TABLE 101 India biopharmaceuticals contract manufacturing market estimates, by service, 2016 - 2020 (USD Million)
  • TABLE 102 India biopharmaceuticals contract manufacturing market forecasts, by service, 2021 - 2028 (USD Million)
  • TABLE 103 India biopharmaceuticals process development market estimates, by service, 2016 - 2020 (USD Million)
  • TABLE 104 India biopharmaceuticals process development market forecasts, by service, 2021 - 2028 (USD Million)
  • TABLE 105 India biopharmaceuticals contract manufacturing market estimates, by product, 2016 - 2020 (USD Million)
  • TABLE 106 India biopharmaceuticals contract manufacturing market forecasts, by product, 2021 - 2028 (USD Million)
  • TABLE 107 India biologics contract manufacturing market estimates, by product, 2016 - 2020 (USD Million)
  • TABLE 108 India biologics contract manufacturing market forecasts, by product, 2021 - 2028 (USD Million)
  • TABLE 109 Latin America biopharmaceuticals contract manufacturing market estimates, by source, 2016 - 2020 (USD Million)
  • TABLE 110 Latin America biopharmaceuticals contract manufacturing market forecasts, by source, 2021 - 2028 (USD Million)
  • TABLE 111 Latin America biopharmaceuticals contract manufacturing market estimates, by service, 2016 - 2020 (USD Million)
  • TABLE 112 Latin America biopharmaceuticals contract manufacturing market forecasts, by service, 2021 - 2028 (USD Million)
  • TABLE 113 Latin America biopharmaceuticals process development market estimates, by service, 2016 - 2020 (USD Million)
  • TABLE 114 Latin America biopharmaceuticals process development market forecasts, by service, 2021 - 2028 (USD Million)
  • TABLE 115 Latin America biopharmaceuticals contract manufacturing market estimates, by product, 2016 - 2020 (USD Million)
  • TABLE 116 Latin America biopharmaceuticals contract manufacturing market forecasts, by product, 2021 - 2028 (USD Million)
  • TABLE 117 Latin America biologics contract manufacturing market estimates, by product, 2016 - 2020 (USD Million)
  • TABLE 118 Latin America biologics contract manufacturing market forecasts, by product, 2021 - 2028 (USD Million)
  • TABLE 119 Brazil biopharmaceuticals contract manufacturing market estimates, by source, 2016 - 2020 (USD Million)
  • TABLE 120 Brazil biopharmaceuticals contract manufacturing market forecasts, by source, 2021 - 2028 (USD Million)
  • TABLE 121 Brazil biopharmaceuticals contract manufacturing market estimates, by service, 2016 - 2020 (USD Million)
  • TABLE 122 Brazil biopharmaceuticals contract manufacturing market forecasts, by service, 2021 - 2028 (USD Million)
  • TABLE 123 Brazil biopharmaceuticals process development market estimates, by service, 2016 - 2020 (USD Million)
  • TABLE 124 Brazil biopharmaceuticals process development market forecasts, by service, 2021 - 2028 (USD Million)
  • TABLE 125 Brazil biopharmaceuticals contract manufacturing market estimates, by product, 2016 - 2020 (USD Million)
  • TABLE 126 Brazil biopharmaceuticals contract manufacturing market forecasts, by product, 2021 - 2028 (USD Million)
  • TABLE 127 Brazil biologics contract manufacturing market estimates, by product, 2016 - 2020 (USD Million)
  • TABLE 128 Brazil biologics contract manufacturing market forecasts, by product, 2021 - 2028 (USD Million)
  • TABLE 129 MEA biopharmaceuticals contract manufacturing market estimates, by source, 2016 - 2020 (USD Million)
  • TABLE 130 MEA biopharmaceuticals contract manufacturing market forecasts, by source, 2021 - 2028 (USD Million)
  • TABLE 131 MEA biopharmaceuticals contract manufacturing market estimates, by service, 2016 - 2020 (USD Million)
  • TABLE 132 MEA biopharmaceuticals contract manufacturing market forecasts, by service, 2021 - 2028 (USD Million)
  • TABLE 133 MEA biopharmaceuticals process development market estimates, by service, 2016 - 2020 (USD Million)
  • TABLE 134 MEA biopharmaceuticals process development market forecasts, by service, 2021 - 2028 (USD Million)
  • TABLE 135 MEA biopharmaceuticals contract manufacturing market estimates, by product, 2016 - 2020 (USD Million)
  • TABLE 136 MEA biopharmaceuticals contract manufacturing market forecasts, by product, 2021 - 2028 (USD Million)
  • TABLE 137 MEA biologics contract manufacturing market estimates, by product, 2016 - 2020 (USD Million)
  • TABLE 138 MEA biologics contract manufacturing market forecasts, by product, 2021 - 2028 (USD Million)
  • TABLE 139 South Africa biopharmaceuticals contract manufacturing market estimates, by source, 2016 - 2020 (USD Million)
  • TABLE 140 South Africa biopharmaceuticals contract manufacturing market forecasts, by source, 2021 - 2028 (USD Million)
  • TABLE 141 South Africa biopharmaceuticals contract manufacturing market estimates, by service, 2016 - 2020 (USD Million)
  • TABLE 142 South Africa biopharmaceuticals contract manufacturing market forecasts, by service, 2021 - 2028 (USD Million)
  • TABLE 143 South Africa biopharmaceuticals process development market estimates, by service, 2016 - 2020 (USD Million)
  • TABLE 144 South Africa biopharmaceuticals process development market forecasts, by service, 2021 - 2028 (USD Million)
  • TABLE 145 South Africa biopharmaceuticals contract manufacturing market estimates, by product, 2016 - 2020 (USD Million)
  • TABLE 146 South Africa biopharmaceuticals contract manufacturing market forecasts, by product, 2021 - 2028 (USD Million)
  • TABLE 147 South Africa biologics contract manufacturing market estimates, by product, 2016 - 2020 (USD Million)
  • TABLE 148 South Africa biologics contract manufacturing market forecasts, by product, 2021 - 2028 (USD Million)

List of Figures

  • FIG. 1 Market research process
  • FIG. 2 Information Procurement
  • FIG. 3 Primary research pattern
  • FIG. 4 Market research approaches
  • FIG. 5 Value chain based sizing & forecasting
  • FIG. 6 QFD modelling for market share assessment
  • FIG. 7 Market summary
  • FIG. 8 Market trends & outlook
  • FIG. 9 Market segmentation & scope
  • FIG. 10 Market driver relevance analysis (Current & future impact)
  • FIG. 11 Cumulative success rate comparison of biologics with small molecules over time
  • FIG. 12 Number of biologics investigational new drugs, 2005 - 2015
  • FIG. 13 Number of reference products by U.S. biosimilars launchable dates
  • FIG. 14 Market restraint relevance analysis (Current & future impact)
  • FIG. 15 Risk associated with outsourcing services
  • FIG. 16 New technologies adopted by CMOs for fill/finish
  • FIG. 17 Major CMO consolidation deals in 2017
  • FIG. 18 CMOs are trading at strong EV/EBITDA multiples, as of 13 January 2017
  • FIG. 19 Trends in biopharmaceutical industry
  • FIG. 20 Steps in the estimation of capital investment and operating costs
  • FIG. 21 Capital expenditure comparison between SUT and SS - based biologic manufacturing
  • FIG. 22 Operating expense comparison between SUT and SS - based biologic manufacturing
  • FIG. 23 Operating expense - labor comparison between SUT and SS - based biologic manufacturing
  • FIG. 24 Distribution, average USD cost per gram for recombinant protein, 2017 (14th annual survey of 227 biopharmaceutical manufacturing professionals)
  • FIG. 25 Penetration & growth prospect mapping for contract manufacturing service, 2017
  • FIG. 26 SWOT Analysis, By Factor (political & legal, economic and technological)
  • FIG. 27 Porter's Five Forces Analysis
  • FIG. 28 Global biopharmaceuticals contract manufacturing market: Source outlook key takeaways
  • FIG. 29 Global biopharmaceuticals contract manufacturing market: Source movement analysis
  • FIG. 30 Global mammalian source market, 2016 - 2028 (USD Million)
  • FIG. 31 Global non - mammalian source market, 2016 - 2028 (USD Million)
  • FIG. 32 Global biopharmaceuticals contract manufacturing market: Contract manufacturing service type outlook key takeaways
  • FIG. 33 Global biopharmaceuticals contract manufacturing market: Contract manufacturing service type movement analysis
  • FIG. 34 Percentage of bio manufacturers outsourcing some activity of upstream and downstream processing, 2011 - 2016
  • FIG. 35 Global process development market, 2016 - 2028 (USD Million)
  • FIG. 36 Global downstream processing market, 2016 - 2028 (USD Million)
  • FIG. 37 Global upstream processing market, 2016 - 2028 (USD Million)
  • FIG. 38 Global fill & finish operations market, 2016 - 2028 (USD Million)
  • FIG. 39 Global analytical & QC studies market, 2016 - 2028 (USD Million)
  • FIG. 40 Global contract packaging market, 2016 - 2028 (USD Million)
  • FIG. 41 Global biopharmaceuticals contract manufacturing market: Product outlook key takeaways
  • FIG. 42 Global biopharmaceuticals contract manufacturing market: Product movement analysis
  • FIG. 43 Global biologics market, 2016 - 2028 (USD Million)
  • FIG. 44 Year - wise annual approvals for MAb products that are currently marketed in the U.S./EU
  • FIG. 45 Share of MAb - related R&D programs at different development phases, 2015
  • FIG. 46 Global monoclonal antibodies market, 2016 - 2028 (USD Million)
  • FIG. 47 Comparison of R&D pipeline expansion in 2014 and 2015 for recombinant products
  • FIG. 48 Global recombinant proteins market, 2016 - 2028 (USD Million)
  • FIG. 49 Global vaccines market, 2016 - 2028 (USD Million)
  • FIG. 50 Global antisense, RNAi, &molecular therapy market, 2016 - 2028 (USD Million)
  • FIG. 51 Global other product market, 2016 - 2028 (USD Million)
  • FIG. 52 Global biosimilar market, 2016 - 2028 (USD Million)
  • FIG. 53 Regional market place: Key takeaway
  • FIG. 54 Comparison of biopharmaceutical manufacturing facilities region and country wise
  • FIG. 55 Biopharmaceuticals contract manufacturing regional outlook, 2020 & 2028
  • FIG. 56 North America biopharmaceuticals contract manufacturing market, 2016 - 2028 (USD Million)
  • FIG. 57 Number of U.S. pharmaceutical outsourcing M&A transactions
  • FIG. 58 Biopharmaceuticals goods export growth comparison between 2011 and 2014
  • FIG. 59 U.S. biopharmaceuticals contract manufacturing market, 2016 - 2028 (USD Million)
  • FIG. 60 Pros and cons of Canadian pharmaceutical & biopharmaceutical market
  • FIG. 61 Canada Biopharmaceuticals contract manufacturing market, 2016 - 2028 (USD Million)
  • FIG. 62 Europe biopharmaceuticals contract manufacturing market, 2016 - 2028 (USD Million)
  • FIG. 63 Revenue growth of Germany pharmaceutical industry
  • FIG. 64 Germany biopharmaceuticals contract manufacturing market, 2016 - 2028 (USD Million)
  • FIG. 65 France biopharmaceuticals contract manufacturing market, 2016 - 2028 (USD Million)
  • FIG. 66 Factors supporting contract manufacturing/research in Asian countries
  • FIG. 67 Asia Pacific biopharmaceuticals contract manufacturing market, 2016 - 2028 (USD Million)
  • FIG. 68 China Biopharmaceuticals contract manufacturing market, 2016 - 2028 (USD Million)
  • FIG. 69 India biopharmaceuticals contract manufacturing market, 2016 - 2028 (USD Million)
  • FIG. 70 Latin America biopharmaceuticals contract manufacturing market, 2016 - 2028 (USD Million)
  • FIG. 71 Brazil biopharmaceuticals contract manufacturing market, 2016 - 2028 (USD Million)
  • FIG. 72 Middle East & Africa biopharmaceuticals contract manufacturing market, 2016 - 2028 (USD Million)
  • FIG. 73 South Africa biopharmaceuticals contract manufacturing market, 2016 - 2028 (USD Million)
  • FIG. 74 Strategy framework
  • FIG. 75 Participant categorization